Docetaxel and atrasentan versus docetaxel and placebo for men with advanced castration-resistant prostate cancer (SWOG S0421): A randomised phase 3 trial

David I. Quinn*, Catherine M. Tangen, Maha Hussain, Primo N. Lara, Amir Goldkorn, Carol M. Moinpour, Mark G. Garzotto, Philip C. Mack, Michael A. Carducci, J. Paul Monk, Przemyslaw W. Twardowski, Peter J. Van Veldhuizen, Neeraj Agarwal, Celestia S. Higano, Nicholas J. Vogelzang, Ian M. Thompson

*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

141 Scopus citations

Fingerprint

Dive into the research topics of 'Docetaxel and atrasentan versus docetaxel and placebo for men with advanced castration-resistant prostate cancer (SWOG S0421): A randomised phase 3 trial'. Together they form a unique fingerprint.

Keyphrases

Pharmacology, Toxicology and Pharmaceutical Science